TLR9 CpG
Selected indexed studies
- Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy. (Expert Rev Anticancer Ther, 2021) [PMID:33831324]
- Bacterial CpG-DNA licenses TLR9. (Curr Top Microbiol Immunol, 2002) [PMID:12467249]
- CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. (BioDrugs, 2010) [PMID:20623989]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Bacterial CpG-DNA licenses TLR9. (2002) pubmed
- Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy. (2021) pubmed
- CpG oligodeoxynucleotides as TLR9 agonists: therapeutic application in allergy and asthma. (2010) pubmed
- Osteogenic CpG Oligodeoxynucleotide, iSN40, Inhibits Osteoclastogenesis in a TLR9-Dependent Manner. (2024) pubmed
- CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. (2009) pubmed
- Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. (2009) pubmed
- Engineered CpG-Loaded Nanorobots Drive Autophagy-Mediated Immunity for TLR9-Positive Cancer Therapy. (2024) pubmed
- CpG ODN Activates TLR9 and Upregulates TLR3 via the p38 MAPK-ATF3 Signaling Axis to Synergistically Enhance Dendritic Cell Vaccine Efficacy. (2025) pubmed
- CpG ODN 1668 as TLR9 agonist mediates humpback grouper (Cromileptes altivelis) antibacterial immune responses. (2023) pubmed
- TLR9 agonist CpG ODN 2395 promotes the immune response against Leishmania donovani in obesity and undernutrition mice. (2023) pubmed